Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia
Affiliations
Affiliations
- Department of Psychiatry, Faculty of Medicine, Kuwait University, Safat, Kuwait.
Abstract
Background: Previous studies have shown an increase in plasma levels of norepinephrine (NE) after clozapine treatment of schizophrenia. This effect has been suggested to relate to improvement in symptoms.
Methods: To test whether other novel antipsychotic drugs have such an effect, the present experiment examined schizophrenic symptoms and plasma levels of NE before and after 5 weeks of treatment with risperidone or haloperidol.
Results: Risperidone, but not haloperidol, significantly increased plasma NE; however, there was no correlation of this effect with clinical improvement on any symptom scale.
Conclusions: This finding suggests that risperidone shares similar properties with clozapine in enhancing peripheral NE, but that these changes in plasma NE may not be a consistent indicator of atypical antipsychotic drug efficacy.
Similar articles
Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA.Psychiatr Serv. 2001 Nov;52(11):1510-4. doi: 10.1176/appi.ps.52.11.1510.PMID: 11684748 Clinical Trial.
Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC.J Clin Psychiatry. 2004 Jul;65(7):940-7. doi: 10.4088/jcp.v65n0710.PMID: 15291683 Clinical Trial.
Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.Am J Psychiatry. 2002 Feb;159(2):255-62. doi: 10.1176/appi.ajp.159.2.255.PMID: 11823268 Clinical Trial.
Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
Pajonk FG.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):15-23. doi: 10.1016/S0278-5846(03)00164-7.PMID: 14687852 Review.
Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N, Foster RH, Olney R, Plosker GL.Drugs. 2001;61(1):111-61. doi: 10.2165/00003495-200161010-00011.PMID: 11217867 Review.
Cited by
Beauchemin M, Geguchadze R, Guntur AR, Nevola K, Le PT, Barlow D, Rue M, Vary CPH, Lary CW, Motyl KJ, Houseknecht KL.Pharmacol Res. 2020 Feb;152:104589. doi: 10.1016/j.phrs.2019.104589. Epub 2019 Dec 23.PMID: 31874253 Free PMC article.
Unique Effects of Clozapine: A Pharmacological Perspective.
Khokhar JY, Henricks AM, Sullivan EDK, Green AI.Adv Pharmacol. 2018;82:137-162. doi: 10.1016/bs.apha.2017.09.009. Epub 2018 Jan 12.PMID: 29413518 Free PMC article. Review.
Savransky A, Chiappelli J, Rowland LM, Wisner K, Shukla DK, Kochunov P, Hong LE.Psychosom Med. 2017 Sep;79(7):770-776. doi: 10.1097/PSY.0000000000000487.PMID: 28498274 Free PMC article.
Allostatic load and reduced cortical thickness in schizophrenia.
Chiappelli J, Kochunov P, Savransky A, Fisseha F, Wisner K, Du X, Rowland LM, Hong LE.Psychoneuroendocrinology. 2017 Mar;77:105-111. doi: 10.1016/j.psyneuen.2016.11.021. Epub 2016 Nov 24.PMID: 28027496 Free PMC article.
Yoshimura R, Hori H, Katsuki A, Atake K, Nakamura J.Ann Gen Psychiatry. 2016 Jan 14;15:1. doi: 10.1186/s12991-015-0084-9. eCollection 2016.PMID: 26770258 Free PMC article.